Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $75.16 million. The enterprise value is -$110.38 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 84.77 million shares outstanding. The number of shares has increased by 25.76% in one year.
| Current Share Class | 84.77M |
| Shares Outstanding | 84.77M |
| Shares Change (YoY) | +25.76% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 46.42% |
| Float | 67.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.71 |
| Forward PS | 1.81 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.12
| Current Ratio | 3.12 |
| Quick Ratio | 2.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.70 |
Financial Efficiency
Return on equity (ROE) is -347.64% and return on invested capital (ROIC) is -124.54%.
| Return on Equity (ROE) | -347.64% |
| Return on Assets (ROA) | -27.54% |
| Return on Invested Capital (ROIC) | -124.54% |
| Return on Capital Employed (ROCE) | -88.02% |
| Revenue Per Employee | $337,010 |
| Profits Per Employee | -$673,216 |
| Employee Count | 310 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sutro Biopharma has paid $2.34 million in taxes.
| Income Tax | 2.34M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.30% in the last 52 weeks. The beta is 1.58, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | -73.30% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 49.71 |
| Average Volume (20 Days) | 564,384 |
Short Selling Information
The latest short interest is 2.52 million, so 2.97% of the outstanding shares have been sold short.
| Short Interest | 2.52M |
| Short Previous Month | 3.11M |
| Short % of Shares Out | 2.97% |
| Short % of Float | 3.75% |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $104.47 million and -$208.70 million in losses. Loss per share was -$2.51.
| Revenue | 104.47M |
| Gross Profit | 120.95M |
| Operating Income | -165.57M |
| Pretax Income | -206.35M |
| Net Income | -208.70M |
| EBITDA | -158.10M |
| EBIT | -165.57M |
| Loss Per Share | -$2.51 |
Full Income StatementBalance Sheet
The company has $205.13 million in cash and $19.59 million in debt, giving a net cash position of $185.54 million or $2.19 per share.
| Cash & Cash Equivalents | 205.13M |
| Total Debt | 19.59M |
| Net Cash | 185.54M |
| Net Cash Per Share | $2.19 |
| Equity (Book Value) | -32.11M |
| Book Value Per Share | -0.38 |
| Working Capital | 157.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$248.86 million and capital expenditures -$3.16 million, giving a free cash flow of -$252.02 million.
| Operating Cash Flow | -248.86M |
| Capital Expenditures | -3.16M |
| Free Cash Flow | -252.02M |
| FCF Per Share | -$2.97 |
Full Cash Flow StatementMargins
Gross margin is 115.77%, with operating and profit margins of -158.48% and -199.76%.
| Gross Margin | 115.77% |
| Operating Margin | -158.48% |
| Pretax Margin | -197.52% |
| Profit Margin | -199.76% |
| EBITDA Margin | -151.33% |
| EBIT Margin | -158.48% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.76% |
| Shareholder Yield | -25.76% |
| Earnings Yield | -277.67% |
| FCF Yield | -335.30% |
Analyst Forecast
The average price target for Sutro Biopharma is $1.97, which is 122.20% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.97 |
| Price Target Difference | 122.20% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 1.52% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sutro Biopharma has an Altman Z-Score of -5.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.23 |
| Piotroski F-Score | 1 |
